Oct 4, 2022
A strong U.S. dollar is good news for those who want to travel abroad. But for the stock market — which has already plummeted this year — it could lead to further downside according to Morgan Stanley.
“The recent move in the U.S. dollar creates an untenable situation for risk assets that historically has ended in a financial or economic crisis, or both,” Morgan Stanley analysts, led by Mike Wilson, write in a recent note to investors.
Advertisement
Wilson’s team calculates that every 1% gain in the U.S. Dollar Index would have a negative 0.5% impact on company profits.
Thanks for subscribing!
Read the best of Moneywise in 5 minutes or less.
By signing up, you accept Moneywise Terms of Use, Subscription Agreement, and Privacy Policy.
Year to date, the U.S. Dollar Index has surged 16.5% while the S&P 500 has tumbled 23.8%.
The analysts also point out that this greenback strength is happening at a time when central banks around the world are tightening monetary policy, and that does not bode well for the markets.
“If there was ever a time to be on the lookout for something to break, this would be it,” they write.
Wilson’s team expects the S&P 500 to fall to a level of 3,000 to 3,400 later this year or early next year. That implies a further downside of 7.6% to 18.5%.
But that doesn’t mean selling everything. Despite the gloomy outlook, Morgan Stanley still sees upside in quite a few companies. Here’s a look at three that it finds particularly attractive.
Eli Lilly (LLY)
This American pharmaceutical giant commands more than $300 billion in market cap, with products marketed in 120 countries around the world.
Despite the market downturn this year, Eli Lilly is not a beaten-down stock.
In the first six months of 2022, Eli Lilly’s revenue grew 6% year over year. Meanwhile, the company’s adjusted earnings per share improved 12% from a year ago.
Advertisement
Shares are actually up roughly 17% so far in 2022, and Morgan Stanley expects the trend to continue.
Analyst Terence Flynn has an ‘overweight’ rating on Eli Lilly and recently raised his price target from $395 to $412.
Considering that Eli Lilly shares trade at around $321 apiece right now, the new price target implies a potential upside of 28%.
Must Read
- The ultra-rich use these 5 real estate strategies to build wealth while they sleep — you can start with just $100
- Here’s the average income of Americans by age in 2026. Are you keeping up or falling behind?
- Insurance companies profit most from drivers who auto-renew without shopping around. Comparing 100+ quotes takes 2 minutes and costs nothing
Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.
Welltower (WELL)
Welltower is in the real estate business.
The company doesn’t own fancy shopping malls or posh office buildings. Instead, it focuses on health care infrastructure and provides real estate capital to senior housing operators, post-acute care providers, and health systems.
Advertisement
In Q2, Welltower’s revenue grew 29.1% year over year to $1.47 billion. Its same-store net operating income rose 8.7%.
Health care is a recession-resistant sector, so health care-anchored real estate is typically in high demand.
The company also benefits from a major demographic tailwind: population aging.
Morgan Stanley analyst Ronald Kamdem notes that the population aged 75 and older is expected to grow by 4% annually through 2030, which could serve as a catalyst for Welltower’s business.
Advertisement
Kamdem has an ‘overweight’ rating on the company and a price target of $90 — implying a potential upside of 37%.
Exxon Mobil (XOM)
Thanks to strong oil prices, energy stocks have turned out to be some of the best performers of the S&P 500 so far this year.
Exxon Mobil, for instance, is up 44% year to date — and that’s after a strong rally in 2021.
The oil-producing giant gushes profits and cash flow in this commodity price environment. In the first six months of 2022, Exxon earned $23.3 billion in profits, a huge increase from the $7.4 billion in the year-ago period. Free cash flow totaled $27.7 billion for the first half, compared to $13.8 billion in the same period last year.
Solid financials allow the company to return cash to investors. Exxon pays quarterly dividends of 88 cents per share, translating to an annual yield of 3.8%.
Morgan Stanley analyst Devin McDermott has an ‘overweight’ rating on Exxon and recently raised his price target to $113 — roughly 23% above the current levels.
You May Also Like
- JP Morgan sees gold hitting $6,000/oz before 2027 — and a Gold IRA lets you hold the physical metal while deferring the tax bill. Get your free guide from Priority Gold
- Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here’s what it is and the simple steps to fix it ASAP
- Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
- Millionaires under 43 are reshaping investing — just 25% of their portfolios are in stocks. Here’s where their money is going
Jing is an investment reporter for Moneywise. He is an avid advocate of investing for passive income. Despite the ups and downs he’s been through with the markets, Jing believes that you can generate a steadily increasing income stream by investing in high quality companies.
